Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study
- First Online:
- 72 Downloads
In recent years, studies investigated to what extend recommendations for co-prescribing gastroprotective agents in prevention of NSAID-induced gastrointestinal complications are followed in clinical practice. However, only a few studies have also taken into consideration the recommended dose of gastroprotectives prescribed in NSAID-induced ulcer prophylaxis. The aim of our study was to evaluate the prevalence of concomitant use of gastroprotectives with NSAIDs in hospitalized patients, with emphasis on the recommended dose of gastroprotectives for ulcer prophylaxis.
This observational, cross-sectional, drug utilization study included all adult patients receiving NSAIDs hospitalized in the Clinical Hospital Center Zagreb on the day of the study. Data on age, sex, comorbidities, indications for NSAID use, type/dose of NSAIDs and gastroprotectives, history of gastrointestinal events, active gastrointestinal symptoms and risk factors were evaluated.
Main outcome measure
Study outcomes were: (1) prevalence of prescription of gastroprotectives among NSAID-users at risk; (2) prevalence of prescription of gastroprotective in recommended dose; (3) association between risk factors and prescription of GPAs.
The rates of gastroprotectives prescription were significantly higher in NSAID-users with concomitant risk factors as compared to patients without risk factors [47/70 (67.1%) and 8/22 (36.4%), respectively; p = 0.01072]. However, gastroprotection in recommended ulcer-preventive dose was low in both groups [8/70 (11.4%) and 9/92 (9.8%), respectively]. The number of concomitant risk factors did not increase the odds of receiving anti-ulcer therapy (odds ratio 0.7279). Thirty-three percent of patients with concomitant risk factors were not prescribed gastroprotectives. Ibuprofen, NSAID with the lowest risk of inducing gastrointestinal complications, was prescribed in only two patients.
The results indicate high awareness among hospital physicians about possible NSAID-induced gastrointestinal complications, but insufficient knowledge about risk factors related to NSAID-induced gastrointestinal toxicity, recommended dose of gastroprotectives in NSAID-induced ulcer prophylaxis and gastrointestinal toxicity of different types of NSAIDs.
KeywordsAnti-ulcer agents Croatia Drug utilization Gastroprotection Non-steroidal anti-inflammatory agents Prevention Risk factors Secondary care
- 1.National Institute for Clinical Excellence. Guidance on the use of Cyclo-oxygenase (COX) II Selective Inhibitors, Celecoxib, Rofecoxib, Meloxicam and Etodolac for Osteoarthirits and Rheumatatoid Arthritis (Technology Appraisal Guidance, 27). London, NICE.Google Scholar
- 3.Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. the class study: A randomized controlled trial. JAMA 2000;284(10):1247–55.PubMedCrossRefGoogle Scholar
- 5.Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Adenomatous polyp prevention on vioxx (APPROVe) trial investigators. N Engl J Med 2005;352(11):1092–102, Mar 17.Google Scholar
- 6.http://www.fda.gov/cder/drug/infopage/COX2/default.htmGoogle Scholar
- 7.Press release on EMEA review on COX-2 inhibitors. http://www.emea.eu.int/pdfs/human/press/pr/11790804en.pdfGoogle Scholar
- 8.Fries J. NSAID gastropathy: The second most deadly rheumatic disease? epidemiology and risk. Appraisal J Rheum 1991;18(28):6–10.Google Scholar
- 9.Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Non steroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann of Int Med 1991;114:257–63.Google Scholar
- 12.Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241–46.PubMedGoogle Scholar
- 13.Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727–34.PubMedCrossRefGoogle Scholar
- 14.Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719–26.PubMedCrossRefGoogle Scholar
- 20.Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur F, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rew 2002;(4):CD002296.Google Scholar
- 23.Schnitzer TJ, Kong SX, Mavros PP, Straus WL, Watson DJ. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: Analysis of a large United States. Claims Database 2001;23:1984–98.Google Scholar
- 24.http://www.rheumatology.org/publications/guidelines/raguidelines02.asp?aud=memGoogle Scholar
- 25.http://www.rheumatology.org/publications/guidelines/oa-mgmt/oa-mgmt.asp?aud=memGoogle Scholar